Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)

Category Primary study
JournalANNALS OF ONCOLOGY
Year 2020
This article has no abstract
Epistemonikos ID: 005d5f93f58439072123df089939a1dd15314509
First added on: Feb 12, 2025